GoBroad Medical Institute of Hematology (Beijing Center),Beijing GoBroad Boren Hospital's CAR-T therapy is renowned for its comprehensive target selection, covering a wide range of hematologic malignancy targets, including single targets like CD19, CD20, CD22, CD7, CD5, BCMA, GPRC5D, as well as dual-target and triple-target CAR-T therapies. This offers targeted treatment plans for various leukemias, lymphomas, and myelomas. The comprehensiveness of these targets ensures the broad applicability and personalization of the treatment, bringing new hope to patients with different types of hematologic malignancies.

In terms of efficacy, our CAR-T therapy has achieved significant clinical success. From June 2017 to March 2024, a total of 4000 CAR-T clinical research cases have been completed, with a complete remission rate of over 80%.  For example, the complete remission rate for R/R B-ALL patients treated with CD19 CAR-T exceeds 90%. Similarly, treatments using CD7 CAR-T and CD5 CAR-T for T-cell lymphoma patients have also shown good efficacy, improving patients' quality of life and significantly extending survival periods. Additionally, for B-cell lymphomas such as refractory/relapsed diffuse large B-cell lymphoma (DLBCL), our CAR-T therapy has also achieved excellent efficacy, with a high proportion of patients achieving complete remission. This success is attributed to the effective combination of CAR-T therapy with conventional or emerging treatment strategies such as chemotherapy and targeted therapy. These achievements not only mark our progress in treating refractory and relapsed hematologic malignancies but also bring new treatment hope to a broad patient population.

Regarding safety, we have implemented multiple measures to ensure the safety of CAR-T treatment. This includes rigorous pre-treatment evaluation, the implementation of personalized treatment plans, and close monitoring during the treatment process. We pay special attention to the monitoring, prevention, and control of CAR-T-related adverse reactions, as well as proactive management of potential side effects like cytokine release syndrome (CRS) and neurotoxicity. The incidence rate of grade 3 or higher adverse events is less than 5%, ensuring a high level of treatment safety.

Moreover, our treatment is not limited to CAR-T therapy alone but also includes combination with other treatment modalities, such as chemotherapy, targeted therapy, or hematopoietic stem cell transplantation, to enhance treatment outcomes and achieve effective control over complex and refractory hematologic malignancies.